PRELIMINARY PROGRAM



Session 1: Emerging biomarkers in neurodegenerative diseases

- Clinical use of TAU PET: are we ready?
 Matthias Brendel (Munich, Germany)
- Plasma screening: a game changer for diagnostic algorithms. Kaj Blennow (Göteborg, Sweden)
- Tau biomarkers in Alzheimer's disease: towards implementation in clinical trials. Rik Ossenkoppele (Amsterdam, Netherlands)

Session 2: Imaging Prodromal stages of Lewy body diseases

- α-Synuclein Radiotracer Development. *TBC*
- Imaging Biomarkers of conversion in idiopathic rapid-eye-movement sleep behaviour disorders. Dario Arnaldi (Genoa, Italy)
- Multi-Modal Imaging Studies of Brain-first and Body-first subtypes of Parkinson disease.
 Per Borghammer (Aarhus, Denmark)

Session 3: Brain tumors & Neuroinflammation

- Investigational PET tracers in neuro-oncology: present and future.
 Antoine Verger (Nancy, France)
- TSPO imaging in brain tumors.
 Nathalie Albert (Munich, Germany)
- TSPO imaging in neurodegenerative diseases.
 Donatienne Van Weehaeghe (Leuven, Belgium)

Session 4: White matter Imaging in neurodegenerative diseases and beyond

- White matter microstructure disruption in early stage amyloid pathology: is there a role for PET imaging?
 - Lyduine E. Collij (Amsterdam, Netherlands)
- MRI imaging of white matter involvement in Alzheimer's Disease.
 Eric Westman (Stockholm, Sweden)
- Amyloid and TPSO PET imaging in multiple sclerosis.
 Benedetta Bodini (Paris, France)